ticlopidine has been researched along with docetaxel anhydrous in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| De Rosa, G; Napodano, M; Padrini, R; Pengo, V; Plebani, M; Silvano, M; Zambon, CF | 1 |
| Jang, YP; Kim, HJ; Lee, JH; Lee, YJ; Oh, JH; Shin, YJ | 1 |
1 review(s) available for ticlopidine and docetaxel anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for ticlopidine and docetaxel anhydrous
| Article | Year |
|---|---|
A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents; Clopidogrel; Docetaxel; Drug Resistance; Drug-Eluting Stents; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Taxoids; Thiophenes; Thrombosis; Ticlopidine | 2011 |
Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb-drug interactions.
Topics: Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Cyclosporine; Cytochrome P-450 CYP3A; Docetaxel; Drugs, Chinese Herbal; Herb-Drug Interactions; Infusions, Intravenous; Male; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Salvia miltiorrhiza; Taxoids; Ticlopidine | 2011 |